TNFRSF11A and cancer: However, due to the equally important extraskeletal roles of RANKL/RANK signaling; reviewed in [5], preclinical investigations in particular have highlighted this signaling axis as an attractive target for therapeutic intervention in pathologies other than adverse bone resorption: from cancers of the mammary gland [61] to the oral cavity [62, 63].